Alexza Pharmaceuticals partner Grupo Ferrer has launched its Adasuve loxapine inhalation powder in Guatemala, Alexza has announced. The approval in Guatemala is the first that Ferrer has obtained for Adasuve outside of Europe. Ferrer is responsible for regulatory and commercial activities related to Adasuve in the EU, Latin America and CIS countries.
Ferrer Chief Operating Officer Antoni Villaro said, “Launching Adasuve in the first Latin American country is an important milestone in our collaboration with Alexza and our commercial plan for Adasuve. We believe Adasuve provides an important new option for clinicians who treat patients with agitation associated with schizophrenia or bipolar disorder.”
Alexza President and CEO Thomas B. King commented, “Ferrer is making strong progress in securing approvals for Adasuve. We are pleased with their progress, as the Guatemala approval represents Ferrer’s first non-EU submission and approval of Adasuve.”
According to Alexza, the company anticipates that Ferrer will launch the product in more Latin American and countries through 2014 and 2015.
Read the Alexza press release.
